Start with the problem radiation has to solve. An X-ray beam passes through the body and leaves dose along its whole path. So healthy tissue in front of the tumor and behind it is irradiated in order to irradiate the tumor. That spillover matters when the target sits next to the spinal cord, the brainstem, the esophagus, or a child's growing tissue. It sets a ceiling on how much dose can safely be delivered. And dose is what kills the tumor. Protons behave differently. They travel to a depth set by their energy, release most of that energy there, and stop. Almost no dose comes out the far side. National Cancer Center Hospital East installed a cyclotron built for therapy in 1997 and began treating patients in 1998. That put it among the first hospital-based proton centers in the world.
The hospital then worked on how the beam is delivered. Older proton systems spread a wide beam and cut it to the tumor's outline with physical hardware. That wastes dose and follows a complicated shape poorly. The Kashiwa group developed what it describes as the world's first line scanning using a pencil beam. A narrow beam is swept across the target slice by slice. It paints the dose onto the tumor's real three-dimensional shape. Intensity modulated proton therapy was built on that. It uses robust treatment planning, which means the plan is designed to hold up if the body shifts slightly between sessions. Cancers treated here include prostate cancer that has not spread and malignant melanoma of the nasal cavity. The list also covers non-small cell lung cancer, esophageal cancer, squamous cell carcinoma of the head and neck, and liver cancer.
What Japan's national insurance pays for in proton therapy has widened in steps. This is national policy rather than a hospital rule. It applies wherever a patient is treated. Childhood cancers were covered from 2016. Head and neck tumors, prostate cancer, and bone and soft tissue tumors followed in 2018. Several liver, pancreatic, and colorectal cases came in 2022, for cancers that cannot be operated on or that have come back. Early-stage lung cancer that cannot be operated on was added in 2024. Anything outside that list is handled under Japan's advanced medical treatment framework rather than routine coverage. That changes what a patient pays, so it is worth confirming before any travel is booked.
Surgery and drug treatment run at scale alongside the radiation program. The hospital reports around 4,900 operations a year across 12 operating rooms. It uses robot-assisted surgery. It has long concentrated on cancers that are hard to treat well, particularly lung and liver. It keeps a palliative care ward and a lymphedema clinic. Lymphedema is the arm or leg swelling that follows lymph node removal and radiation. It frequently goes untreated elsewhere. When standard options are exhausted, a Department of Experimental Therapeutics runs early-phase trials on the same campus. So being considered for a drug still under study does not require transferring to another institution.